This study, conducted by the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program, aimed to evaluate the prognostic importance of renal function in a broad spectrum of patients with chronic heart failure (CHF). The CHARM program included three component trials: CHARM-Preserved (LVEF >40%), CHARM-Added (LVEF ≤40% and treated with ACE inhibitors), and CHARM-Alternative (LVEF ≤40% and not treated with ACE inhibitors due to intolerance). The analysis focused on 2680 North American patients with baseline creatinine levels below 3.0 mg/dL. The estimated glomerular filtration rate (eGFR) was calculated using the MDRD equation, and its association with cardiovascular (CV) death, hospitalization for worsening CHF, and all-cause mortality was assessed. The results showed that both reduced eGFR and lower LVEF were significant independent predictors of worse outcomes after adjusting for major confounding factors. The risk for CV death, hospitalization for worsening CHF, and all-cause mortality increased significantly below an eGFR of 60 mL/min per 1.73 m². The prognostic value of eGFR was consistent across the three trials, and there was no evidence that the beneficial effect of candesartan was modified by baseline eGFR. The study concluded that impaired renal function is independently associated with heightened risk for death, CV death, and hospitalization for heart failure in patients with CHF, regardless of their LVEF status.This study, conducted by the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program, aimed to evaluate the prognostic importance of renal function in a broad spectrum of patients with chronic heart failure (CHF). The CHARM program included three component trials: CHARM-Preserved (LVEF >40%), CHARM-Added (LVEF ≤40% and treated with ACE inhibitors), and CHARM-Alternative (LVEF ≤40% and not treated with ACE inhibitors due to intolerance). The analysis focused on 2680 North American patients with baseline creatinine levels below 3.0 mg/dL. The estimated glomerular filtration rate (eGFR) was calculated using the MDRD equation, and its association with cardiovascular (CV) death, hospitalization for worsening CHF, and all-cause mortality was assessed. The results showed that both reduced eGFR and lower LVEF were significant independent predictors of worse outcomes after adjusting for major confounding factors. The risk for CV death, hospitalization for worsening CHF, and all-cause mortality increased significantly below an eGFR of 60 mL/min per 1.73 m². The prognostic value of eGFR was consistent across the three trials, and there was no evidence that the beneficial effect of candesartan was modified by baseline eGFR. The study concluded that impaired renal function is independently associated with heightened risk for death, CV death, and hospitalization for heart failure in patients with CHF, regardless of their LVEF status.